Authors

Mark Yarchoan, MD, Johns Hopkins Medicine

Latest:

Novel Agents Being Explored in Advanced Biliary Tract Cancers

Expert panelists provide comprehensive insight on novel targeted agents being investigated in advanced biliary tract cancers.

Alexandra Sokolova

Latest:

Dr Sokolova on the Importance of Genetic Testing in Prostate Cancer

Alexandra Sokolova, MD, discusses the importance of genetic testing in patients with prostate cancer, which patients may benefit most from genetic testing, and how cascade testing can identify additional people who are at risk for developing cancer.

Elise Nassif, MD

Latest:

Dr. Nassif on Examining Gut Microbial Signatures in the Tumor Microenvironment

Elise Nassif, MD, discusses examining gut microbial signatures in the tumor microenvironment.

Andrea Wolf, MD, MPH

Latest:

Dr Wolf on Challenges Conducting Clinical Trials Evaluating Surgery in Mesothelioma

Andrea Wolf, MD, MPH, discusses challenges experienced when conducting randomized trials to assess the role of surgery in mesothelioma management.

Colleen Moretti

Latest:

Darolutamide Plus ADT/Docetaxel Elicits Survival Benefit Across Subgroups in mHSPC

The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.

Ilyas Sahin, MD

Latest:

Dr Sahin on the Design of the Northstar Response Assay in Advanced GI Cancer

Ilyas Sahin, MD, discusses the Northstar Response assay and the future of precision oncology in patients with advanced gastrointestinal cancer.

Helen Heng-Shan Moon, MD

Latest:

Dr. Moon on the Future of Care in Prostate Cancer

Helen Heng-Shan Moon, MD, discusses the future of care in prostate cancer.

Michelle T. Chi, MD

Latest:

Practical Considerations for Fellows Treating VTE

Most hematology/oncology fellows will care for patients with venous thromboembolism throughout their training and long after their graduation from fellowship. Here are some practical considerations when treating a patient with an acute VTE.

Michael Atkins, MD

Latest:

Dr Atkins on the Rationale of Investigating Nivolumab/Ipilimumab in RCC

Michael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

Mark Alwardt

Latest:

Oral Oncolytics Will Require Health Care System to Adapt

Judging from the drug pipeline, the future of oncology is oral chemotherapy.

Allison A. DiPasquale, MD

Latest:

Dr DiPasquale on the Continued Investigation into Cerianna PET Scans in Breast Cancer

Allison A. DiPasquale, MD, discusses the continued evaluation of Cerianna positron emission tomography scans in patients with breast cancer and highlights the need for a multidisciplinary approach when treating patients in this population.

Ricardo Costa, MD, MSc

Latest:

Dr. Costa on the Implications of the KEYNOTE-522 Trial in TNBC

Ricardo Costa, MD, MSC, discusses the implications of the phase 3 KEYNOTE-522 trial trial in patients with high-risk, early-stage triple-negative breast cancer.

Stephen Hursting, PhD, MPH

Latest:

Dr Hursting on Weight Loss Drugs and the Potential to Reduce Obesity-Related Breast Cancer

R. Tyler Hillman, MD, PhD

R. Tyler Hillman, MD, PhD, is assistant professor in the Department of Gynecologic Oncology and Reproductive Medicine of the Division of Surgery at The University of Texas MD Anderson Cancer.

Latest:

Dr Hillman on Identifying New Therapy Candidates in Adult-Type Granulosa Cell Tumor

R. Tyler Hillman, MD, PhD, discusses ways of identifying new drug therapy candidates in patients with adult-type granulosa cell tumor of the ovary.

Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute

Latest:

Monitoring Patients for Interstitial Lung Disease

Experts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.

Katie Kelley, MD

Latest:

Patient Profile 3: Advanced HCC Treated With Cabozantinib in Second Line

Centering discussion on the final patient profile, panelists consider how they select optimal therapy in the second-line setting of advanced hepatocellular carcinoma.

Cheryl Saenz, MD

Latest:

Dr. Saenz on the Need for Ongoing Research Efforts in Cervical Cancer

Cheryl Saenz, MD, discusses the need for ongoing research efforts in cervical cancer.

Huma Q. Rana, MD, MPH

Latest:

Dr. Rana on Using Age at Diagnosis to Guide the Utility of Genetic Testing in Prostate Cancer

Huma Q. Rana, MD, MPH, discusses the use of age at diagnosis to guide the utility of genetic testing in men with prostate cancer.

Devon Womack

Latest:

Providing Timely Cancer Care Access Is Crucial Amid Growing Patient Volume

A closer look at some of the approaches being used across The US Oncology Network to improve patient access can provide helpful insight into how practices can meet the growing need for their services.

Hannah Walker-Mimms, MS

Latest:

Dr Walker-Mimms on Outcomes With Filanesib in Ewing and Clear Cell Sarcoma

Hannah Walker-Mimms, MS, discusses a study revealing that Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types.